In a cohort of 146 breast cancer patients (Lund cohort), 20 we found significantly higher inter-tumor variability in β-values among the CpG sites in the clock set, as compared to the CpG sites not included in the clock set (Fig. 2C). This evidence concerns the gene CLOCK and breast carcinoma.